MARKET

TRDA

TRDA

Entrada Therapeutics, Inc.
NASDAQ
10.60
+0.53
+5.26%
After Hours: 10.60 0 0.00% 17:43 02/06 EST
OPEN
10.30
PREV CLOSE
10.07
HIGH
10.71
LOW
10.19
VOLUME
192.21K
TURNOVER
--
52 WEEK HIGH
14.27
52 WEEK LOW
4.930
MARKET CAP
405.12M
P/E (TTM)
-4.2342
1D
5D
1M
3M
1Y
5Y
1D
Entrada Therapeutics CEO to Speak at Guggenheim Biotech Summit
Reuters · 4d ago
Weekly Report: what happened at TRDA last week (0126-0130)?
Weekly Report · 6d ago
Entrada Therapeutics initiated with an Outperform at Oppenheimer
TipRanks · 01/28 12:35
Weekly Report: what happened at TRDA last week (0119-0123)?
Weekly Report · 01/26 09:17
Weekly Report: what happened at TRDA last week (0112-0116)?
Weekly Report · 01/19 09:19
Entrada Therapeutics: Advancing DMD and DM1 Pipeline with Emerging Ophthalmology Assets Supports Buy Rating and $20 Target
TipRanks · 01/12 22:35
Weekly Report: what happened at TRDA last week (0105-0109)?
Weekly Report · 01/12 09:18
Capricor Therapeutics: A High Risk/High Reward Name
Seeking Alpha · 01/10 09:12
More
About TRDA
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in establishing a class of medicines, which engages intracellular targets. Its Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The Company is advancing a robust development portfolio of RNA-, antibody- and enzyme-based programs for the potential treatment of neuromuscular, ocular, metabolic and immunological diseases, among others. It is engaged in preclinical lead optimization efforts in both neuromuscular and non-neuromuscular disease and discovery efforts to advance platform applications. Its lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne who are exon 44, 45, 50 and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Webull offers Entrada Therapeutics Inc stock information, including NASDAQ: TRDA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TRDA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TRDA stock methods without spending real money on the virtual paper trading platform.